Online citations, reference lists, and bibliographies.
DOI: 10.1002/hed.25337

Pretreatment Metabolic Tumor Volume As A Prognostic Factor In HPV‐associated Oropharyngeal Cancer In The Context Of AJCC 8th Edition Staging

John M Floberg, Todd A DeWees, Re-I Chin, Adam A. Garsa, Farrokh Dehdashti, Brian Nussenbaum, Peter J. Oppelt, Douglas R. Adkins, Hiram A. Gay, W. L. Thorstad
Published 2018 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND This study evaluates the prognostic significance of 18 F-fluorodeoxyglucose-positron emission tomography ([F-18]FDG-PET)-derived metabolic tumor volume (MTV) in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinomas (OPSCCs) in the context of AJCC 8th edition staging. METHODS We performed a retrospective study of HPV-associated OPSCCs treated with postoperative or definitive radiation. The prognostic significance of pretreatment MTV for freedom from recurrence (FFR), freedom from distant metastasis (FFDM), and overall survival (OS) was determined using Kaplan-Meier analysis. Multivariate analysis (MVA) was performed using Cox regression. RESULTS In this 153-patient cohort, stratifying by the optimum MTV (24 cm3 ) was prognostic for FFR (P = .0002), FFDM (P = .001), and OS (P < .0001). Metabolic tumor volume (MTV) was prognostic of FFR in AJCC 8th edition stage I/II (P = .03), and stage III patients (P = .04). On multivariate analysis only MTV was a significant factor for OS. CONCLUSION Metabolic tumor volume (MTV) is a significant prognostic factor in HPV-associated OPSCCs, independent of AJCC 8th edition stage.
This paper references
NON-NESTED HYPOTHESES1
Quang Hong Vuong (1989)
10.1016/j.ijrobp.2011.10.023
Validation that metabolic tumor volume predicts outcome in head-and-neck cancer.
Chad Tang (2011)
10.1016/S1470-2045(15)00560-4
Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study.
B O'Sullivan (2016)
10.1186/s40463-014-0033-7
Metabolic tumour volume as a prognostic factor for oral cavity squamous cell carcinoma treated with primary surgery
Han Zhang (2014)
10.1002/cncr.30931
Comparison of unilateral versus bilateral intensity‐modulated radiotherapy for surgically treated squamous cell carcinoma of the palatine tonsil
R. Chin (2017)
10.2307/1912557
Likelihood Ratio Tests for Model Selection and Non-Nested Hypotheses
Quang Hieu Vuong (1989)
10.1088/1361-6560/aa73cc
Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics.
Michael R. Folkert (2017)
10.2967/jnumed.111.101402
18F-FDG PET/CT Metabolic Tumor Volume and Total Lesion Glycolysis Predict Outcome in Oropharyngeal Squamous Cell Carcinoma
Remy Lim (2012)
10.1016/j.ijrobp.2015.08.033
Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Bhishamjit S. Chera (2015)
10.1200/JCO.2014.58.6412
Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.
Shao Hui Huang (2015)
10.1097/PAS.0b013e3181e84652
p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status.
James S. Lewis (2010)
10.1016/j.radonc.2011.05.040
Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity.
James D Murphy (2011)
10.1002/hed.24465
Prognostic value of FDG-PET volumetric parameters in patients with p16-positive oropharyngeal squamous cell carcinoma who received curative resection followed by postoperative radiotherapy or chemoradiotherapy.
Kyung Hwan Kim (2016)
10.1002/ijc.22980
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen.
Serge J. Smeets (2007)
10.2967/jnumed.112.119289
Textural Features of Pretreatment 18F-FDG PET/CT Images: Prognostic Significance in Patients with Advanced T-Stage Oropharyngeal Squamous Cell Carcinoma
Nai-Ming Cheng (2013)
10.1007/s13566-012-0065-4
Prognostic value of 18F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma
Adam A. Garsa (2012)
10.1007/s13139-010-0063-7
Prognostic Value of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated by Surgery
Kyu-Ho Choi (2011)
10.1016/j.ijrobp.2014.12.023
Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522.
David L. Schwartz (2015)
10.1002/hed.24486
Reevaluation of postoperative radiation dose in the management of human papillomavirus-positive oropharyngeal cancer.
Re-I Chin (2016)
10.1001/jamaoto.2013.4973
Pathologically determined tumor volume vs pathologic T stage in the prediction of outcome after surgical treatment of oropharyngeal squamous cell carcinoma.
Iain J Nixon (2013)
10.1016/j.ijrobp.2008.10.060
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer.
Trang H. La (2008)
10.1016/j.cden.2017.08.008
Human Papillomavirus and Oropharyngeal Cancer.
Takako Imai Tanaka (2018)
10.1200/JCO.2014.55.3925
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
Phuc Felix Nguyen-Tan (2014)
10.1200/JCO.2012.44.0164
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.
B O'Sullivan (2013)
10.3857/roj.2011.29.4.243
FDG-PET/CT as prognostic factor and surveillance tool for postoperative radiation recurrence in locally advanced head and neck cancer
Giwon Kim (2011)
10.1016/S0360-3016(03)00346-8
Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study.
I. Frank Ciernik (2003)
10.1007/s00259-014-2961-x
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Ronald Boellaard (2014)
10.1200/JCO.2016.66.6081
Human Papillomavirus and Oropharyngeal Cancer Stage.
Maura L. Gillison (2016)
10.2967/jnumed.113.133801
Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Head and Neck Cancer: A Systematic Review and Meta-Analysis
Kyoungjune Pak (2014)
10.1016/j.radonc.2012.02.009
Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation.
B O'Sullivan (2012)
10.2967/jnumed.111.099531
18F-FDG Metabolic Tumor Volume and Total Glycolytic Activity of Oral Cavity and Oropharyngeal Squamous Cell Cancer: Adding Value to Clinical Staging
Elizabeth H Dibble (2012)
10.2967/jnumed.114.141424
Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy
Robert Jeraj (2015)
10.1002/hed.24287
Tumor volume as a predictor of survival in human papillomavirus-positive oropharyngeal cancer.
Kara S. Davis (2016)
10.1016/S0167-9473(98)00096-6
An application of changepoint methods in studying the effect of age on survival in breast cancer
Cécile Parent Contal (1999)
10.1007/978-3-319-40618-3_10
HPV-Mediated (p16+) Oropharyngeal Cancer
B O'Sullivan (2017)
10.1016/j.yped.2010.12.093
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
James A. Stockman (2012)
10.1200/JCO.2015.64.6448
Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories.
Kristina R Dahlstrom (2016)



This paper is referenced by
10.1016/j.radonc.2019.05.019
The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status.
Jon M Moan (2019)
10.1007/978-981-15-3188-0_10
PET in the Diagnosis of Head and Neck Cancer
Tetsuro Sekine (2020)
10.1007/978-981-15-3188-0
Diagnostic Imaging in Head and Neck Cancer
Hiroya Ojiri (2020)
Semantic Scholar Logo Some data provided by SemanticScholar